The Urticaria Severity Score

A sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria

Sunit P. Jariwala, Heather Moday, M. Lourdes De Asis, Jason Fodeman, Golda Hudes, Gabriele De Vos, David L. Rosenstreich

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Despite the existence of numerous dermatology-specific quality-of-life questionnaires, there exists a need for a well-validated instrument to evaluate and monitor patients with chronic urticaria. Objective: To develop and validate a novel chronic urticaria-specific questionnaire, the Urticaria Severity Score (USS). Methods: The USS was developed with 12 questions and 7 response options per question included in the final questionnaire. The USS was pilot tested on 28 patients with symptomatic chronic urticaria, and a modified version was tested in 80 patients. In this latter group, the USS was compared with the previously validated Dermatology Life Quality Index (DLQI). Patients completed both questionnaires at baseline and at follow-up (median, 2 weeks). Spearman rank correlation tests were used to compare the USS with the DLQI. At a subsequent visit, 9 additional patients completed the USS to evaluate test-retest reliability. Results: There was a positive correlation between the USS and DLQI at baseline (r = 0.64) and follow-up (r = 0.69). The test-retest reliability correlation for the USS was adequate (r = 0.96) (P = .001). The USS was more sensitive in detecting symptom improvement than the DLQI. The mean (SD) "raw score" change from baseline to follow-up for the USS was 9.95 (12.80), whereas the mean (SD) change from baseline to follow-up for the DLQI was 2.25 (4.87). Conclusions: The USS is a valid and reliable instrument for monitoring urticaria severity. The USS is more sensitive than the DLQI for quantifying urticaria severity and may be more applicable in the evaluation of urticaria-specific treatment efficacy.

Original languageEnglish (US)
Pages (from-to)475-482
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume102
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Urticaria
Dermatology
Quality of Life
Therapeutics
Surveys and Questionnaires
Reproducibility of Results

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

The Urticaria Severity Score : A sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria. / Jariwala, Sunit P.; Moday, Heather; De Asis, M. Lourdes; Fodeman, Jason; Hudes, Golda; De Vos, Gabriele; Rosenstreich, David L.

In: Annals of Allergy, Asthma and Immunology, Vol. 102, No. 6, 06.2009, p. 475-482.

Research output: Contribution to journalArticle

@article{46396d05dd454f88a33e4af87fbef665,
title = "The Urticaria Severity Score: A sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria",
abstract = "Background: Despite the existence of numerous dermatology-specific quality-of-life questionnaires, there exists a need for a well-validated instrument to evaluate and monitor patients with chronic urticaria. Objective: To develop and validate a novel chronic urticaria-specific questionnaire, the Urticaria Severity Score (USS). Methods: The USS was developed with 12 questions and 7 response options per question included in the final questionnaire. The USS was pilot tested on 28 patients with symptomatic chronic urticaria, and a modified version was tested in 80 patients. In this latter group, the USS was compared with the previously validated Dermatology Life Quality Index (DLQI). Patients completed both questionnaires at baseline and at follow-up (median, 2 weeks). Spearman rank correlation tests were used to compare the USS with the DLQI. At a subsequent visit, 9 additional patients completed the USS to evaluate test-retest reliability. Results: There was a positive correlation between the USS and DLQI at baseline (r = 0.64) and follow-up (r = 0.69). The test-retest reliability correlation for the USS was adequate (r = 0.96) (P = .001). The USS was more sensitive in detecting symptom improvement than the DLQI. The mean (SD) {"}raw score{"} change from baseline to follow-up for the USS was 9.95 (12.80), whereas the mean (SD) change from baseline to follow-up for the DLQI was 2.25 (4.87). Conclusions: The USS is a valid and reliable instrument for monitoring urticaria severity. The USS is more sensitive than the DLQI for quantifying urticaria severity and may be more applicable in the evaluation of urticaria-specific treatment efficacy.",
author = "Jariwala, {Sunit P.} and Heather Moday and {De Asis}, {M. Lourdes} and Jason Fodeman and Golda Hudes and {De Vos}, Gabriele and Rosenstreich, {David L.}",
year = "2009",
month = "6",
doi = "10.1016/S1081-1206(10)60120-2",
language = "English (US)",
volume = "102",
pages = "475--482",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "6",

}

TY - JOUR

T1 - The Urticaria Severity Score

T2 - A sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria

AU - Jariwala, Sunit P.

AU - Moday, Heather

AU - De Asis, M. Lourdes

AU - Fodeman, Jason

AU - Hudes, Golda

AU - De Vos, Gabriele

AU - Rosenstreich, David L.

PY - 2009/6

Y1 - 2009/6

N2 - Background: Despite the existence of numerous dermatology-specific quality-of-life questionnaires, there exists a need for a well-validated instrument to evaluate and monitor patients with chronic urticaria. Objective: To develop and validate a novel chronic urticaria-specific questionnaire, the Urticaria Severity Score (USS). Methods: The USS was developed with 12 questions and 7 response options per question included in the final questionnaire. The USS was pilot tested on 28 patients with symptomatic chronic urticaria, and a modified version was tested in 80 patients. In this latter group, the USS was compared with the previously validated Dermatology Life Quality Index (DLQI). Patients completed both questionnaires at baseline and at follow-up (median, 2 weeks). Spearman rank correlation tests were used to compare the USS with the DLQI. At a subsequent visit, 9 additional patients completed the USS to evaluate test-retest reliability. Results: There was a positive correlation between the USS and DLQI at baseline (r = 0.64) and follow-up (r = 0.69). The test-retest reliability correlation for the USS was adequate (r = 0.96) (P = .001). The USS was more sensitive in detecting symptom improvement than the DLQI. The mean (SD) "raw score" change from baseline to follow-up for the USS was 9.95 (12.80), whereas the mean (SD) change from baseline to follow-up for the DLQI was 2.25 (4.87). Conclusions: The USS is a valid and reliable instrument for monitoring urticaria severity. The USS is more sensitive than the DLQI for quantifying urticaria severity and may be more applicable in the evaluation of urticaria-specific treatment efficacy.

AB - Background: Despite the existence of numerous dermatology-specific quality-of-life questionnaires, there exists a need for a well-validated instrument to evaluate and monitor patients with chronic urticaria. Objective: To develop and validate a novel chronic urticaria-specific questionnaire, the Urticaria Severity Score (USS). Methods: The USS was developed with 12 questions and 7 response options per question included in the final questionnaire. The USS was pilot tested on 28 patients with symptomatic chronic urticaria, and a modified version was tested in 80 patients. In this latter group, the USS was compared with the previously validated Dermatology Life Quality Index (DLQI). Patients completed both questionnaires at baseline and at follow-up (median, 2 weeks). Spearman rank correlation tests were used to compare the USS with the DLQI. At a subsequent visit, 9 additional patients completed the USS to evaluate test-retest reliability. Results: There was a positive correlation between the USS and DLQI at baseline (r = 0.64) and follow-up (r = 0.69). The test-retest reliability correlation for the USS was adequate (r = 0.96) (P = .001). The USS was more sensitive in detecting symptom improvement than the DLQI. The mean (SD) "raw score" change from baseline to follow-up for the USS was 9.95 (12.80), whereas the mean (SD) change from baseline to follow-up for the DLQI was 2.25 (4.87). Conclusions: The USS is a valid and reliable instrument for monitoring urticaria severity. The USS is more sensitive than the DLQI for quantifying urticaria severity and may be more applicable in the evaluation of urticaria-specific treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=67549109369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549109369&partnerID=8YFLogxK

U2 - 10.1016/S1081-1206(10)60120-2

DO - 10.1016/S1081-1206(10)60120-2

M3 - Article

VL - 102

SP - 475

EP - 482

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -